Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carfilzomib
Drug ID BADD_D00367
Description Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Indications and Usage Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate.
Marketing Status Prescription
ATC Code L01XG02
DrugBank ID DB08889
KEGG ID D08880
MeSH ID C524865
PubChem ID 11556711
TTD Drug ID D00UVA
NDC Product Code 50384-0180; 52076-6251; 76075-103; 50384-0230; 54893-0037; 76055-0035; 63552-009; 16436-0116; 63552-035; 50384-0260; 55111-985; 11722-059; 50384-0220; 50384-0210; 50384-0190; 67262-0010; 76075-102; 50384-0240; 42385-731; 76075-101
Synonyms carfilzomib | PR-171 | PR171 | Kyprolis
Chemical Information
Molecular Formula C40H57N5O7
CAS Registry Number 868540-17-4
SMILES CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3) NC(=O)CN4CCOCC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Clostridium difficile colitis11.02.02.004; 07.19.01.0040.000533%Not Available
Coccydynia15.02.01.0040.000533%Not Available
Cold sweat08.01.03.024; 23.02.03.0020.000533%Not Available
Confusional state19.13.01.001; 17.02.03.0050.008792%
Constipation07.02.02.001--
Coronary artery disease02.02.01.001; 24.04.04.006--Not Available
Cough22.02.03.0010.011456%
Cystitis20.03.02.002; 11.01.14.0010.002398%
Death08.04.01.0010.030857%
Decreased immune responsiveness10.02.01.0410.001332%Not Available
Decubitus ulcer23.03.11.0060.000533%Not Available
Dehydration14.05.05.0010.008792%
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.001--Not Available
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.000799%Not Available
Dilatation ventricular02.04.02.0260.000533%Not Available
Diplopia17.17.01.005; 06.02.06.0020.001066%Not Available
Discomfort08.01.08.0030.002398%Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000208%
Diverticulitis11.01.07.003; 07.10.02.0010.001066%Not Available
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.007--
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.0050.000533%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry mouth07.06.01.002--
Dry throat22.02.05.004; 07.06.01.0050.000533%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 18 Pages